Adverse effects of systemic therapy in a patient with urothelial bladder cancer and chronic kidney disease – a case report - Takeaways - MDSpire

Adverse effects of systemic therapy in a patient with urothelial bladder cancer and chronic kidney disease – a case report

  • By

  • Martyna Najmrocka

  • Aleksandra Semeniuk

  • Rafał Stec

  • July 2, 2026

  • 0 min

Share

  • 1

    Immune checkpoint inhibitors (ICIs) are a therapeutic alternative for urothelial bladder cancer patients ineligible for cisplatin-based chemotherapy.

  • 2

    A 72-year-old man with CKD developed severe immune-related adverse events after three cycles of nivolumab treatment.

  • 3

    Clinical symptoms included diffuse myalgia, limb weakness, and elevated troponin and ALT levels, necessitating glucocorticosteroid treatment.

  • 4

    Multidisciplinary evaluation revealed chronic steroid toxicity and secondary testosterone deficiency during treatment.

  • 5

    The case highlights the diagnostic challenges in distinguishing irAEs from CKD progression, emphasizing the need for coordinated care.

Original Source(s)

Adverse effects of systemic therapy in a patient with urothelial bladder cancer and chronic kidney disease – a case report

  • by Martyna Najmrocka, Aleksandra Semeniuk, Rafał Stec

  • July 2, 2026

Related Content

Crucial role of IL-6, IL-8, IL-11 and leptin in tumor microenvironment in a group of patients with GEP-NETs- crosstalk between inflammation and cancer

Development and internal validation of a prognostic nomogram incorporating F-NLR and HAGR scores in patients with oral squamous cell carcinoma: a single-center retrospective cohort study

Durable stable disease and immune activation in metastatic uveal melanoma treated with tebentafusp: case report